[New York, New York] – Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug...

New independent directors Christof Bircher and Nneka Ukpai bring significant expertise in business strategy, corporate finance and...

NEW YORK, NY / ACCESSWIRE / January 7, 2024 /  Laxxon Medical, a leading pharma-technology company pioneering a new generation of...

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Laxxon Medical Corp., a leading pharma technology platform company focusing on oral drug...

Laxxon is seeking out-licensing opportunities for lead asset LXM.2, or co-developments projects with 3DSP platform technology SPID® at...

NEW YORK, NY / ACCESSWIRE / October 9, 2024 /  Laxxon Medical , a US-based pharma-technology company pioneering a new generation of...

The cooperation between Laxxon and Adare enables the clinical and commercial production of advanced drug delivery systems at Adare’s cGMP fa

Learn more about Laxxon Medical's groundbreaking 3D printed oral GLP-1 asset, offering an alternative to injections in obesity treatments.

Counterfeit medicine is a threat to public health. Technologies like 3D printing and QR codes help protect both patients and drug integrity.

Laxxon Medical announced its participation in the 2024 BIO International Convention, to showcase its LXM.2 asset to potential partners.